Understanding the Patient Experience of Receiving Clinically Actionable Genetic Results from the MyCode Community Health Initiative, a Population-Based Genomic Screening Initiative

http://www.mdpi.com/1830408

Vall d' Hebron Institute of Oncology -Barcelona ,Spain reveals optimistic records:
Omomyc as the first MYC-targeted therapy to successfully complete a phase I clinical trial :
MYC inhibitor Omomyc (OMO-103)

https://vhio.net/2022/10/26/omomyc-as-the-fir...a-phase-i-clinical-trial/

//quote:
Elena Garralda, Director of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, enrolled 22 patients to a phase I clinical trial in April 2021 to determine the safety, tolerability, pharmacokinetics and pharmacodynamics, and proof-of-concept of OMO-103. These heavily pre-treated patients had a range of solid tumors including pancreatic, bowel, and non-small cell lung cancers, and had received at least three prior lines of therapy. Results of the CT scans of the 17 evaluable patients showed that 8 had stable disease, with the treatment having halted tumor growth.

“While it is still very early days to assess the activity of Omomyc, we are observing stabilization of disease in some patients. Notably, one patient with pancreatic cancer remained on the study for more than six months and his tumor shrank by eight per cent with an eighty-three per cent decrease in the quantity of circulating tumour DNA in the bloodstream,” said Elena Garralda, Principal Investigator of VHIO’s Early Clinical Drug Development Group and first author of this present study that was carried out in collaboration with two other Spanish sites.
//unquote

The clinical application of polygenic risk scores: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG)

https://doi.org/10.1016/j.gim.2023.100803

What doctors wish patients knew about precision medicine | American Medical Association News Wire, July 2023

For this installment, two physicians took time to discuss what patients need to know about precision medicine. They are:

Mira Irons, MD, a pediatrician, medical geneticist, president, and CEO of the College of Physicians of Philadelphia. In a prior role, Dr. Irons served as chief health and science officer at the AMA.

Jordan Laser, MD, an anatomic, clinical, and molecular genetic pathologist and chair of the Personalized Medicine Committee for the College of American Pathologists,

https://www.ama-assn.org/delivering-care/prec...-about-precision-medicine

Family of Henrietta Lacks settles HeLa cell lawsuit with biotech giant, lawyer says - CBS Minnesota


https://www.cbsnews.com/minnesota/news/family...tific/?intcid=CNR-01-0623